Limaprost

Limaprost (OP1206) is a PGE1 analogue and a potent and orally active vasodilator. Limaprost increases blood flow and inhibits platelet aggregation. Limaprost pain relief, has antianginal effects, and can be used for ischaemic symptoms research^[1][2]. In Vitro: Limaprost inhibits the IL-1-mediated induction of nerve growth factor (NGF) in a concentration-dependent manner with an IC₅₀ value of 70.9 ?nM human IVD cells^[3]. In Vivo: Limaprost (OP1206) given orally at more than 100 μg/kg relieves Argipressin-induced ST depression of rat electrocardiogram (ECG)^[1].
Intra-coronary injection of Limaprost (OP1206; 1-100 ng/kg) in dogs results in a remarkable increase of coronary blood flow without any influence on heart rate, blood pressure, myocardial oxygen consumption and redox potential^[1].
Resistance in both large and small vessels of dog coronary artery is decreased by intravenous injection of Limaprost (OP1206; 1-3 mg/kg)^[1].
Platelet aggregation, adhesiveness, bleeding time, and thrombocytopenia induced by ADP and collagen infusion in guinea-pigs are inhibited by oral administration of Limaprost (OP1206) at the same doses or doses less than those relieving Argipressin-induced ST depression of ECG^[1].